Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

Phase 3 Completed 800 enrolled Sanofi Daiichi Pharmaceuticals · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting).

Timeline

Start: 2004-07
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clopidogrel	Small molecule	75 mg	—

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

Summary

Timeline

Drugs

Indications